We are a clinical stage pharmaceutical company developing a topical formulation of the immunomodulator squaric acid dibutyl ester for the prevention of recurrent cold sores (herpes labialis) and other infections caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2.
More than 9 Million people in the U.S. suffer with 6 or more herpes labialis outbreaks every year with no existing medications indicated for the prevention of outbreaks.
Our drug SQX770 is unique. A single topical application to the arm, not the lip or face, has been shown in clinical trials to prevent cold sore outbreaks (oral herpes) in people with frequent outbreaks for 3 months.
The SQX770 formulation was co-invented by the company’s founder Hugh McTavish in a desperate attempt to treat his own frequent cold sores. Hugh originally tested the drug on himself, and found that even after the first use of the drug his cold sores became much less frequent and much less intense. So he founded the company to try to bring this drug to everyone who suffers from frequent cold sores.